Vyepti (eptinezumab)
- Region
- 🇪🇺 EU
- Active substance
- eptinezumab
- Company
- H. Lundbeck A/S
- Status
- Authorised
- Therapeutic area
- Migraine Disorders
- CHMP opinion
- Thu 11 Nov 2021
- EU approval
- Mon 24 Jan 2022
- Application
- EMEA/H/C/005287
- ATC
- N02CD
- Official record
- www.ema.europa.eu
Indication
Vyepti is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.
Regulatory milestones
No milestones recorded in the last year.
Follow Vyepti
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.